NEWS | BEAM Alliance

NEWS

MilliDrop receives €1.9 million from Bpifrance to develop a rapid diagnosis test for sepsis

MilliDrop receives €1.9 million from Bpifrance to develop a rapid diagnosis test for sepsis

Paris, France, September 12, 2018 – MilliDrop, which designs and develops cell culture solutions based on millifluidics technology for bacteriological research and diagnosis purposes, announces it has been awarded €1.9 million in non-dilutive financing from Bpifrance to accelerate the development of its blood infection diagnosis system for sepsis.

Millidrop receives this funding as a laureate of the “Concours d’Innovation” (Innovation Challenge) in the health category with its project “Droplet-Based Integrated Diagnosis from Blood Culture to Antibiogram”, that was backed by the Medicen Paris Région competitiveness cluster. MilliDrop’s goal is to speed up the microbiological diagnosis process for patients with sepsis.

Full PR available here